Tuesday, February 09, 2010 10:44:25 AM EST
New User? Register  |  Sign In
NJBIZ
Sign-up for eNews Alerts!
Advertising
 • Media Kit
 • Print Ad Info
 • Web Ad Info
 • Event Sponsorships
 • Production Info
Customer Service
 • Register
 • Contact Us
 • Change of Address
 • Print Subscriptions
 • Print Renewals
 • Free Trial
 • Gift Subscriptions
 • Help & FAQ
Search Archives
MORE FROM NJBIZ
PEOPLE WHO READ THIS...
Also read these stories:

Barr Gets Canadian Approval for Generic Oral Contraceptive

By João-Pierre Ruth
8/28/2007
 Print this page  |   E-mail to a friend  |  Submit news tips  |  Send a letter to the editor  |  

Barr Pharmaceuticals Inc. (NYSE: BRL) in Woodcliff Lake says its subsidiary, Barr Laboratories Inc., has received approval for its abbreviated new drug submission from the Therapeutic Products Directorate of Health Canada for Portia, a generic equivalent of Min-Ovral tablets. Min-Ovral is an oral contraceptive for women made by Wyeth Laboratories.

Barr will manufacture Portia and Apotex Inc. will market the product in Canada. Barr will receive a royalty on Canadian sales. Portia has been available since 2002 in the United States, where it is approved as a generic version of Nordette, an oral contraceptive marketed by Duramed Pharmaceuticals Inc. Nordette has the same active ingredients as Min-Ovral, levonorgestrel and ethinyl estradiol.

Shares of Barr were down $1.42 to $50.17 in early afternoon trading.

724 people have read this article.
 Print this page  |   E-mail to a friend  |  Submit news tips  |  Send a letter to the editor  |  

For article reprints, please contact our reprint coordinator at Wright’s Reprints: 1-877-652-5295.
Return To Top
Journal Publications Inc.
© 2010 Journal Publications Inc. All information on this site are copyright of Journal Publications Inc. All images are the sole property of Journal Publications Inc. and no rights are granted for any use without the express written consent of Journal Publications Inc.
Email Marketing by Listrak
Email Marketing by Listrak™